Australia's most trusted
source of pharma news
Sunday, 08 September 2024
Posted 25 July 2024 AM
Telix is going through a cracker month, as investors buy into its growth narrative.
The Australian radiopharmaceutical giant raised $650 million in funding by issuing convertible bonds. The result comes a month after the company pulled its NASDAQ IPO due to lackluster interest.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.